igf-1 lr3 cycle length + MASS = CRAZY Growth? #askDave igf-1 lr3 cycle length desensitization

Phase II human trials of thymosin beta-4 (TB-500's parent molecule) have been conducted examining tissue repair rates, with studies reporting acceleration of repair in patients with pressure ulcers, stasis ulcers, and epidermolysis bullosa wounds, though detailed results remain limited in peer-reviewed literature

These are key factors for lasting energy and less mid-day fatigue

doi: 10.1186/gb-2005-6-4-r35 118 MihreteabM.StubblefieldB

Therefore, the antioxidant species were used at different doses, so further clinical studies are needed to identify the minimum useful dose to be used as monotherapy or in combination with conventional therapies